More on CYTR

- Summary
- Chart
- Profile
- Historical


- Earnings (-161.3% Growth)
- Ratings (8.3 Score)
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (8/3/16 *Est.)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

CYTR Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 68.16M
Marketable securities 0
Proceeds from sale of RXi, received January 6, 2011
Receivable 1M
Investment in Adventrx Pharmaceuticals, at market
Income taxes recoverable
Interest receivable 0
Prepaid expenses and other current assets 3.63M
Total current assets 72.79M
Equipment and furnishings, net 1.68M
Goodwill 183.78K
Other assets 689.33K
Total assets 75.34M
Current liabilities:
Accounts payable 5.96M
Accrued expenses and other current liabilities 6.28M
Warrant liabilities 877.73K
Total current liabilities 18.85M
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding 0
Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 66.58K
Additional paid-in capital 411.25M
Accumulated comprehensive income, net of tax
Treasury stock, at cost (633,816 shares)
Accumulated deficit -377.74M
Total stockholders' equity 33.58M
Total liabilities and stockholders' equity 75.34M